Evaluation of the efficacy of daikenchuto (TJ-100) for the prevention of paralytic ileus after pancreaticoduodenectomy: A multicenter, double-blind, randomized, placebo-controlled trial
Tsutomu Fujii(University of Toyama), Hiroki Yamaue(Wakayama Medical University), Seiko Hirono(Wakayama Medical University), Yoshiyasu Ambo(Hokkaido University of Science), Masayuki Sho(Nara Medical University), Yasuhiro Shimizu(Aichi Cancer Center), Manabu Kawai(Wakayama Medical University), Junichi Sakamoto(Tokai Central Hospital), Hidetoshi Eguchi(Osaka Gakuin University), Sohei Satoi(Kansai Medical University), Mari S. Oba(Yokohama City University), Naru Kondo(Hiroshima University), Ken‐ichi Okada(Wakayama Medical University), Satoshi Morita(Kyoto University), A‐Hon Kwon(Kansai Medical University), Jiro Ohuchida(University of Miyazaki), Hiroaki Nagano(Yamaguchi University), Yoshiaki Murakami(Hiroshima University), Yoshiyuki Nakajima(Tokyo Women's Medical University), Yasuhiro Kodera(Nagoya Medical Center)
Cited by 3
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632